We are developing a pipeline of disruptive biological approaches based on data driven biology, to address the unmet medical needs in oncology, for
hematological malignancies and solid tumors.
. We are committed to provide oncologists and patients with immunotherapies that are novel, efficacious and prolong life expectancy.
We have created a next-generation, robust bi- and multi-specific antibody technology platform, BiXAb®, thanks to a proprietary computational modelling approach. Our ‘Plug-and-Play’ BiXAb® technology generates bi- and multi-specific antibodies, with minimal engineering, from any pair of monoclonal antibodies as building blocks, in a timely and cost-effective manner.
